Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Medicenna Thera Corp (MDNAF)

Medicenna Thera Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms GlobeNewswire - Thu Jun 11, 6:00AM CDT

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026 GlobeNewswire - Wed Jun 3, 6:00AM CDT

NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses  Up to 80 patients with...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs GlobeNewswire - Thu May 28, 8:10AM CDT

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet GlobeNewswire - Fri May 22, 6:00AM CDT

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities GlobeNewswire - Tue May 19, 6:00AM CDT

Base shelf prospectus is accessible, and prospectus supplement will be accessible within two business days on SEDAR+ 1 TORONTO and HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Announces the Launch of a Marketed Public Offering of Securities GlobeNewswire - Wed May 13, 3:01PM CDT

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma GlobeNewswire - Tue May 12, 6:00AM CDT

NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/2...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026 GlobeNewswire - Thu Apr 30, 6:30AM CDT

TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 GlobeNewswire - Tue Apr 21, 6:30AM CDT

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing the systemic tolerability profile Head-to-head non-human...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference GlobeNewswire - Tue Apr 14, 6:30AM CDT

TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused...

MDNAF : 0.2960 (+2.17%)
MDNA.TO : 0.4100 (unch)

Barchart Exclusives

Marvell Stock Soars 228% This Year. Data Center Momentum Is Still Hot, But Future Upside May Be Limited. Barchart - 10 minutes ago
Marvell’s growth trajectory remains solid. It will continue to benefit from AI infrastructure spending and strong bookings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.